HA Assoc Co Booklet 2017 (1)

2017

Bioscience Companies

located on the campus of HudsonAlpha

grow with us

Testimonials stimulating How This Book Works: Contents

An opportunity to be with other scientists and It’s really easy and it’s encouraged to go around, The companies located on HudsonAlpha Institute for Biotechnology’s Medical Devices &
other companies and other entrepreneurs talk to your fellow scientist neighbors, and really campus can be divided into four sub-sectors of life sciences: Research, Equipment
was something we couldn’t pass up. It has get help or anything that you need from the other Testing, & Medical Labs; Medical Devices & Equipment; Drugs & Phar-
just been a great opportunity for us as we people that work here. It’s really nice to work in maceuticals; and Bioscience-related Distribution. Alimetrix ..................................... 5
grow to learn from others. As we say, ‘As the a place where everybody is friendly and we work Companies are listed below according to their sub-sector. Throughout CFDRC ......................................... 9
tide rises, all the ships rise with it.’ as a team. the book, companies are listed in alphabetical order and categorized by Gene Capture .......................... 16
- Sara Cooper, PhD an icon located on the top corner of each page. iCubate, Inc. .............................. 17
- Marshall Schreeder Microarrays, Inc. ....................... 25
Faculty Investigator Research, Testing, Ploid .......................................... 28
& Medical Labs SynVivo ...................................... 33
Chief Executive Officer & Co-Founder, Coversant Bio unprecedented Thermo Fisher Scientific, Inc. .. 34
Acclinate Genetics .................... 4
dynamic If you want to be entrepreneurial, if you want to start BioDynami .................................. 7 Bioscience-related
companies, if you really want to grow technologies, this is Clinical Services Lab .............. 12 Distribution
the right field for that. Jim Hudson has done a fantastic IMIDomics ................................. 18
job of creating that kind of environment. I didn’t realize iRepertoire, Inc. ....................... 19 Concero Scientific ..................... 10
[Many] people can paint a vision, but at HudsonAlpha they [have how unique it was until looking back to when it wasn’t iXpress Genes ......................... 20 Conversant Bio ......................... 11
been supporting those visions]. That was displayed [through the Kailos Genetics ....................... 22 Diatherix Laboratories, Inc. .... 13
Institute’s] investment in the Smith Family Clinic [for Genomic there, before HudsonAlpha. - Troy Moore Molecular Logic ...................... 26 Envision Genomics .................. 14
Medicine, which utilizes] genomic medicine to [help diagnosed] Chief Scientific Officer, Kailos Genetics Prozone Water Products, Inc. ... 29 Kailos Genetics ....................... 22
patients with rare, undiagnosed [disorders]. Hearing that vision Smith Family Clinic ................. 31 Kymanox .................................... 23
and then seeing them act on it really [says] something unique collaborative Sulfilatec ................................... 32 Leavendary ................................ 24
about what this place [is] about. [This is a great match for] Trideum Biosciences ............... 36 transOMIC Technologies ........ 35
Envision Genomics, [which is leveraging] that infrastructure to Volatile Analysis Corporation .. 38 Ubiquity Genomics ................. 37
help bring what we are learning here at HudsonAlpha to the rest Jackson Conference Center .... 21
Huntsville is a pretty unique town. Drugs &
of market to help patients. - Aaron Fisher I really want my kids to grow up Pharmaceuticals
Vice President for Business Development,
Envision Genomics somewhere that was cool and fun ARIEL Precision Medicine ......... 6
and not too big, but also a place Celsion Corporation ................... 8
cutting-edge where I can do great science. Foresight Biosciences, Inc. ..... 15
MVW Nutritionals .................... 27
- Liz Worthey, PhD Founder, Serina Therapeutics, Inc. ......... 30

Chief Product Development Officer, Envision Genomics For more information about companies on HudsonAlpha’s campus, contact
Ross Ivey | [email protected] | 256.327.9480

2 BIOSCIENCE COMPANIES LOCATED AT HUDSONALPHA grow with us 3

Exponential growth in hereditary cancer detection I love that they’re Alimetrix is a CLIA and CAP accredited molecular diagnostic company whose mission is
and diagnostics has created significant demand doing such to alleviate patient suffering through the development of state of the art diagnostic tools.
by medical professionals and their patients for Utilizing unique disease insight, coupled with proprietary technologies, Alimetrix is able to
fast and accurate hereditary cancer detection and [innovative] research provide exceptionally accurate, actionable test results in a timely manner. Being armed with
diagnostic services. here at HudsonAlpha. finely detailed and accurate information allows clinicians to gain a clear understanding of the
Acclinate Genetics aims to create a more efficient therapeutic needs of the patient. As part of our clinician partnership we seek to provide best-
market for connecting healthcare providers in They have cutting- in-class diagnostic assays, helping to facilitate better patient outcomes and actively reduce
need of genomic screening and diagnostic services edge technology and patient suffering.
with the specialized laboratories performing such just really making a Alimetrix provides Relevant Diagnostics Empowering Actionable Therapy®.
services. Acclinate leverages a comprehensive difference in people’s
network of specialized partner labs to provide CONTACT LEADERSHIP Samantha Bond, MS
healthcare providers with a centralized source for lives. Joel Peek, PhD
fast, accurate, and reliable genetic screening and - Susan Hiatt, PhD www.alimetrix.com Director of Microbiology
diagnostic services. 1.844.443.6663 Chief Executive Officer,
Senior Scientist President & Founder Jonas Boateng, PhD
LEADERSHIP [email protected]
Preti Jain, PhD CONTACT Mark McQuain, MS, PhD Director of Next-Generation
Sequencing (NGS)
Chief Scientific Officer, Co-Founder www.acclinategenetics.com Chief Technical Officer
256.690.5608 Jason Scott, MS
Del Smith, PhD Carol Quinter, MSC, PhD
Vice President, Clinical
President, Co-Founder Laboratory Director of Clinical Operations
Services
4 BIOSCIENCE COMPANIES LOCATED AT HUDSONALPHA
Richard Spera, MD, FACP

Medical Director

grow with us 5

ARIEL is an advanced diagnostics laboratory and bioinformatics services BioDynami Corporation is a biotechnology company that provides innovative solutions for life
company providing genomic-based tests that aid in the diagnosis, sciences research and development. Currently, BioDynami is focusing on next generation sequencing
monitoring and treatment of Complex Chronic Disease and Disorders. Our (NGS) and molecular cloning. We provide reagents for NGS, DNA cloning, and PCR cloning. We also
mechanistic diagnostic process approach is intended to enable informed offer services for NGS library construction, custom vector design, and DNA cloning. Our goal is to
intervention prior to the development of end-stage outcomes. provide the best solutions in the field to make Research and Development life easier.
We believe that ARIEL’s technologies can lead a paradigm shift from single gene (Mendelian) Next Generation Sequencing
genetics to multifaceted, complicated gene to gene interactions that interface with familial and
environmental factors to provide a more comprehensive view of disease trajectory and precise • Quick and efficient DNA library prep reagents for diverse needs
therapeutic options. Our SMART-MD platform integrates the patient’s symptoms and genetics • Library quantification reagents
(derived through Next Generation Sequencing of more than 700 gene targets) with complex • NGS services
medical information that includes systems modeling, machine learning and other advanced Molecular Cloning
reporting technology. The process tests one patient and his or her disease behavior against • Effective and simple cloning kits for any type of DNA fragments
databases of well-mapped, complex disease patterns to help determine both the underlying • Cloning vectors for common DNA cloning and large DNA cloning
causes of the disease and the optimal treatment plan. • Cloning services
While headquartered in Pittsburgh, PA, ARIEL has an office within the HudsonAlpha Institute for DNA Ladders
Biotechnology, a 152 acre campus located in Huntsville, Alabama that is shared by some of the • Ready-to-load DNA ladders: cover from 20 bp to 20 kb with easy identification band
world’s “genomics thought leaders,” forward-thinking entrepreneurs and inventive educators. Services
We are leveraging their state-of-the-art Genomic Services Laboratory to develop and validate • Next Generation Sequencing: DNA library prep, sequencing
each of our tests prior to commercialization. The HudsonAlpha laboratories provide access to • Cloning: any type of DNA fragment cloning; vector design and construction
the most advanced scientific tools available in the field.

LEADERSHIP John “Tory” Moore, CFA CONTACT CONTACT LEADERSHIP
Jessica M. Gibson, MBA Lisa Chen, MBA
Chief Financial Officer www.arielmedicine.com www.biodynami.com
Chief Executive Officer 256.327.9569 256.872.0805 Chief Executive Officer, Co-Founder
Jessica LaRusch, PhD
Mark Haupt, MD [email protected] Jun Song, MD, PhD
Lead Genetic Scientist
Chief Medical Officer Chief Technology Officer

6 BIOSCIENCE COMPANIES LOCATED AT HUDSONALPHA grow with us 7

Celsion is a fully-integrated oncology company focused on developing a CFDRC’s mission is to develop and commercialize innovative
portfolio of innovative cancer treatments, including directed chemotherapies, technologies. Most of the company’s work is performed through highly
immunotherapies, and RNA or DNA based therapies. Celsion has three platform competitive research contracts from government agencies. Three core
technologies for development of novel nucleic, acid-based immunotherapies focus areas are aerospace & defense, biomedical & life sciences, and
and other anti-cancer DNA or RNA therapies, including LTSL, TheraPlas™, energy & materials.
and TheraSilence™.

Technology Product Pipeline Bio and Energy Technologies

LTSL , which stands for lysolipid thermally sensitive liposomes, Celsion’s pipeline includes two clinical-stage candidates targeting various 25 patents in the following key areas:
is a unique liposomal technology used in Celsion’s lead oncology indications and two platform technologies for the development of
product, ThermoDox®. LTSL allows for the triggered release novel nucleic acid-based immunotherapies and other anti-cancer DNA/RNA • Microfluidics – miniaturized sample preparation and manipulation including cell-based assays; leading
of a drug payload through low temperature (just above body therapies. These include: product technology is SynVivo.
temperature) heat activation. LTSL is a proprietary heat-activated ThermoDox® is a proprietary heat-activated liposomal encapsulation of
liposomal encapsulation of doxorubicin, which is currently in Phase III doxorubicin. Celsion is currently enrolling a 550 patient. Phase III pivotal • Electrochemical Devices – Variety of power sources including biologically inspired prototypes; leading
development for the treatment of primary liver cancer. study of ThermoDox® in combination with radiofrequency ablation in product technology is Bio-Battery.
TheraPlas™ is a versatile technology platform for the delivery of primary liver cancer. ThermoDox® is also being evaluated in two Phase II
DNA and messenger RNA (mRNA) therapeutic via synthetic non- studies in recurrent chest wall breast cancer in the U.S. and Europe. • Chem/Bio Sensors – Optical and electrical sensors for detection of chemical and biological agents.
viral carriers and is uniquely capable of providing cell transfection GEN-1 for Ovarian and Brain Cancers - Positive safety and encouraging • Advanced Software Tools – Custom software tools for design analysis of material, devices, and systems.
capability for double-stranded DNA plasmids and large therapeutic Phase I results with GEN-1 given as monotherapy in patients with
RNA segments such as mRNA. peritoneally metastasized ovarian cancer. A Phase Ib trial of GEN-1 in Testing Products
TheraSilence™ is a versatile technology platform focused on combination with PEGylated doxorubicin in patient with platinum-resistant
delivering synthetically generated small inhibitory RNAs (siRNAs), ovarian cancer has completed enrollment. The Company plans to initiate SynVivo is currently being tested by a number SynVivo: Realistic, dynamic, cell-based
microRNAs, microRNA mimics, and related molecules that additional clinical studies with GEN-1 as part of a first line treatment for of academic collaborators, small biotechs and assays enabling accurate studies of cellular
can regulate protein expression by exploiting endogenous cell ovarian cancer as well as a combination treatment for platinum resistant pharma. behavior, drug delivery and accelerating drug
mechanisms. ovarian cancer. GEN-1 has also demonstrated encouraging preclinical Bio-Battery is receiving application develop- development cycles.
activity in glioblastoma multiforme (brain cancer). ment funding from a defense contractor. Bio-Battery: Biologically inspired power
sources utilizing enzymes as catalysts to
convert readily available fuels such as sugar
LEADERSHIP and alcohol directly into electrical energy.
Michael H. Tardugno Jeffrey W. Church

Chairman, President & Chief Senior Vice President & Chief
Executive Officer Financial Officer

Khursheed Anwer, PhD, MBA Jason Fewell, PhD CONTACT

Executive Vice President & Chief Vice President, Preclinical Research www.cfdrc.com
Scientific Officer 256.726.4800
CONTACT LEADERSHIP Kapil Pant, PhD
Nicholas Borys, MD [email protected] Sameer Singhal
www.celsion.com Vice President of Biomedical &
Senior Vice President & Chief 609.896.9100 Vice President & Chief Energy Technologies
Medical Officer Operating Officer

8 BIOSCIENCE COMPANIES LOCATED AT HUDSONALPHA grow with us 9

I began to notice Conversant Bio provides biospecimens and ancillary services to
that there was researchers focused on oncology, hematology and immunology
a lot of money, research. In 2013, Conversant Bio expanded services to include
energy, and talent neurology, endocrinology and pulmonology. Conversant Bio provides
being poured into primary tissues and cells matched with the clinical information
HudsonAlpha and scientists need to better validate their research so new drugs can reach the patient bedside more
I realized that I quickly. Most projects are prospective in nature; Conversant Bio collects and processes specimens
needed to skate that meet each researcher’s specific criteria for patient selection and sample preparation.
where the puck is Conversant Bio also continues to expand its ability to source normal biospecimens to support general
and that I needed to immunology research. Conversant Bio is currently involved in more than 160 active preclinical or
be a part of it. clinical studies with scientists in the U.S., Europe and Asia. Examples of past research include:
- Jerry Jenkins, PhD
Concero Scientific’s mission is safeguarding Non-small Cell Lung Cancer Breast Cancer, Renal Cell Carcinoma
the warfighter and the homeland from Genome Analysis Group Lead Longitudinal collection of blood, sputum Collection of tissue and treatment outcome
biothreats by accelerating prevention, and tumor tissue helped develop companion information to validate prognostic test that
response and control solutions for infectious CONTACT diagnostic for EGFR targeted therapy in Phase identifies Herceptin and Sutent responders/
diseases and bioagents through research, I trials. Proved that diagnostic assay is possible non-responders for breast cancer and renal
development and integration of cutting-edge www.conceroscientific.com on less invasive specimens (blood/sputum). cell carcinoma, respectively.
life science discoveries. 256.327.0468
[email protected] Glioblastoma Multiforme, Hepatocellular Mesothelioma
LEADERSHIP Carcinoma, Breast Cancer (triple negative), Collection of blood and tumor tissue to validate
Lynn Hudson Colorectal Cancer PI3 kinase biomarker for novel therapeutic
compound. Results were extremely promising
Chief Executive Officer Collection of blood and tumor tissue to identify and researcher plans to push drug from Phase
additional disease indications for lung cancer I to Phase III trial because of unmet medical
10 BIOSCIENCE COMPANIES LOCATED AT HUDSONALPHA drug in a Phase III trial. need.

CONTACT LEADERSHIP Jay Scherer
Marshall Schreeder, Jr.
www.conversantbio.com Chief Operating Officer
866.838.2798 Chief Executive Officer, Co-
Founder Will Taylor
[email protected]
Luke Doiron Chief Financial 0fficer

Chief Commercial Officer, Co-
Founder

grow with us 11

The HudsonAlpha Clinical Services Lab, LLC, provides clinical genomic Diatherix is an innovative, CLIA certified, molecular diagnostic laboratory utilizing
testing for the improvement of health through precision medicine. The proprietary TEM-PCR™ (Target Enriched Multiplex Polymerase Chain Reaction)
CSL is CAP accredited and CLIA licensed. It is one of the few clinical technology for precise detection of infectious diseases, linking diagnostics
labs offering whole genome sequencing with clinical interpretation by a team of board-certified to therapeutics.
clinical and molecular geneticists. Our analysis and interpretation pipeline was developed
in-house and has become a model of the industry and our in-house development team is TEM-PCR Benefits:
continually building, refining, and enhancing the existing pipeline to incorporate new genomic TEM-PCR technology is a unique, multiplex amplification platform designed to overcome the
information and to provide the most nimble tools for genomic analysis. challenges that exist with conventional laboratory methods and real-time PCR applications.
Services and Technologies
Sequencing is carried out in HudsonAlpha’s CSL under the direction of Shawn Levy, PhD. Levy Improved Speed and Accuracy of Laboratory Results Lead To:
is a faculty investigator and director of the Genomic Services Laboratory (GSL) at HudsonAlpha
Institute for Biotechnology in Huntsville, Alabama. The HudsonAlpha Clinical Services Lab • Improved patient outcomes
offers personalized genomic sequencing and analysis for the identification of rare undiagnosed • Cost reduction and avoidance
and misdiagnosed disease. The lab was established in 2015 in response to the growth of the • Reduced antibiotic utilization
field of genomic medicine and increased demand for sequencing. Whole genome sequencing • Increased patient satisfaction
is performed on the Illumina HiSeq X Ten platform, which is CAP/CLIA approved for clinical • Greater clinical value
use.
Diatherix Distinctions:
LEADERSHIP Liz Worthey, PhD
Shawn Levy, PhD • Simultaneous identification of bacteria, viruses, parasites, Candida, and antibiotic resistance
Assistant Lab Director for • Detection of bacteria in the presence of antibiotics
Executive Director Informatics • Increased sensitivity and specificity
• Simplicity of single sample collection
Bruce Korf, MD, PhD Andy Crouse, PhD • One-day results (determined by sample receipt)

Lab Director Chief Scientific Leader Business LEADERSHIP Traci Tyree
Development Director Dennis Grimaud
David Bick, MD Chief Financial Officer
CONTACT CONTACT Chief Executive Officer
Assistant Lab Director Donald R. Stalons, PhD,
www.clinicallab.org www.diatherix.com Randy Ward, MT (ASCP) D(ABMM), MPH
Molly Schroeder, PhD 256.327.0438 866.979.4242
[email protected] President & Chief Operations Vice President of Operations,
Assistant Lab Director Officer Clinical Laboratory Director

Stanley Lu

Chief Information Officer

12 BIOSCIENCE COMPANIES LOCATED AT HUDSONALPHA grow with us 13

Envision Genomics is a comprehensive genomic medicine enabler for Foresight Biosciences commercializes technology for glycobiology research with an
children’s hospitals committed to improving the quality and reducing emphasis on creating tools for engineering glycoconjugates that alter the biodistribution of
the cost of healthcare by unlocking the genomic sequence for more administered therapeutics.
effective patient care. Envision offers clinical implementation, clinical
grade sequencing, informatics, and precision medicine care delivery training enabling physicians to Technology
practice true precision medicine. Most FDA approved protein therapeutics are glycosylated. Natural protein glycoconjugates
Envision Genomics is committed to improving the quality & reducing the cost of healthcare by have very specific structures that affect their function and distribution. Therapeutic proteins
unlocking the utility and value of the genomic sequence for patient care. derived from nonhuman cells often exhibit improper glycosylation that require modification
prior to administration.
Envision Genomics is Designed To:
The company’s technology facilitates protein posttranslational modification,
• Help clinicians and healthcare providers diagnose rare disease, end diagnostic odysseys or reverse glycoconjugation, and glycan analysis.
misdiagnoses through integration of the practice of genomic medicine when and how they need it.
Product & Service
• Provide partner organizations with the clinical end-to-end expertise, infrastructure and resources The company offers benchtop assays for glycoprotein terminal fingerprint analysis,
necessary to implement and deploy cutting edge, market differentiating clinical genomic services. recombinant enzymes, and convenient kits for identifying, repairing and modifying protein
glycosylation.
• Support practicing preventative care.

Envision Genomics is not just a service provider—we are a comprehensive genomic medicine
enabler.

LEADERSHIP David Bick, MD CONTACT CONTACT LEADERSHIP
Grace E. Terrell, MD Ronny Hughes, PhD
Founder, Chief Medical Officer www.envisiongenomics.com www.foresight-bio.com
Founder, Chief Executive Officer [email protected] 256.327.9404 President
Aaron Fisher
Howard Jacob, PhD [email protected] Ernest Curto, PhD
Chief of Staff to the Chief
Founder, President & Chief Executive Officer Senior Scientist
Scientific Officer
Shawn Levy, PhD
Elizabeth Worthey, PhD
Founder
Founder, Chief Product
Development Officer Bruce R. Korf, MD, PhD

Jill Tapper, MHA, CG (ASCP) Founder

Founder, Chief Operating Officer

14 BIOSCIENCE COMPANIES LOCATED AT HUDSONALPHA grow with us 15

GeneCapture is developing a portable medical device to rapidly identify pathogens iCubate® is changing molecular diagnostics by taking on the rapidly moving
causing infections in humans. Our patented CAPTURE™ (Confirm Active Pathogens world of infectious disease. With groundbreaking technology and a flexible
Through Unamplified RNA Expression) technology allows faster, inexpensive options for platform, iCubate provides a better diagnostic tool for the doctor, laboratory
Point of Care infection detection. Validation tests are underway. director and patient while saving the hospital money and time in the lab.
Our mission is to bring ‘infection detection’ out of the lab and directly to the patient
location whether that’s at a doctor’s office, an airport, a cruise ship, or a battlefield. Technology
GeneCapture is pursuing a commercial product path and developing a specialized version
of the hardware for the Department of Defense. Applications for the technology exist in iCubate’s proprietary core technology, arm-PCR, was developed by the company’s founder, Jian
human health, animal health, agriculture and bio-defense. Han, M.D., Ph.D. This technology identifies 30 genes in one assay. It has received the Frost and
SullivanAward for Innovation and made the company a “Private Company to Watch” by Piper Jaffray.

Product

iCubate’s fully automated system provides DNA extraction, multiplexed amplification, hybridization and
detection all in a closed cassette. While infectious disease detection is the company’s initial focus, the
flexibility of its platform and development process allows the pursuit of many opportunities including food
safety, agriculture and defense. iCubate has a solid pipeline of products including assays for additional
infectious diseases and foodborne pathogens.

The iCubate System Provides: • easy-to-use platform with only minutes of
• sample in/answer out capability hands-on time by the lab technician
• highly-multiplexed arm-PCR technology
to test multiple pathogens at one time • a small footprint on valuable and limited
• technology enabling scientists to create bench space in the lab
assays that meet changing market needs
• a closed system that eliminates the risk of
sample contamination and false positives

LEADERSHIP CONTACT CONTACT Outlook
Peggy Sammon
www.genecapture.com www.icubate.com The future looks bright for iCubate. The company earned
Chief Executive Officer, Founder 256.783.4506 256.603.7042 anticipates FDA clearance in the summer second quarter
[email protected] of 2017 for the platform and first panel, which detects and
Krishnan Chittur, PhD [email protected] identifies pathogenic bacteria causing bloodstream infection.
After FDA clearance, iCubate is will working toward early market
Chief Technology Officer, Founder acceptance in the U.S., continued product pipeline development
and execution of the company’s Asian and European marketing
Paula Koelle sales plans.

Senior Scientist LEADERSHIP Carter Wells
Jian Han, MD, PhD
16 BIOSCIENCE COMPANIES LOCATED AT HUDSONALPHA Chief Executive Officer
Founder, Chairman
of the Board

grow with us 17

IMIDomics is a unique company tackling Immune-Mediated Inflammatory Diseases (IMIDs). As an iRepertoire uses immune repertoire sequencing technology to access the body’s
innovative leader in discovery and application of biomarkers and new targets to monitor and cure immunological memory, or “logbook” of all past infection and disease. Sequencing
IMIDs, we create value through the combination of the world’s largest IMID biobank, extensive the immune repertoire can yield insights into the nature of the body’s immune
relevant clinical expertise, high-throughput genomic and genetic analysis, and intellectual response to disease and infection. The future market for iRepertoire will be in
property. clinical and research applications that require immune assessment such as drug treatment
We are building the world’s most extensive and comprehensive IMIDs database of novel content. monitoring, immune monitoring after stem cell transplantation, vaccine studies, and
Our Focus is on six common IMIDs: Rheumatoid Arthritis (RA), Crohn’s Disease (CD), Ulcerative biomarker development.
Colitis (UC), Psoriasis (PS), Psoriatic Arthritis (PA), and Systemic Lupus Erythematosus (SLE).
We apply ultrahigh-throughput genomic analyses to biological materials from the IMID Biobank iRepertoire sells reagent kits and services for immune repertoire amplification of B cell and T
and we measure genetic and functional genomics on a genome-wide scale. We include among cell receptor sequences, which are compatible with downstream Next Generation Sequencing
others deep measurements of mRNA, microRNA, and long non-coding RNA transcripts, DNA (NGS). iRepertoire has also automated immune repertoire amplification and extraction on their
methylation, Epigenetic markers, and Immune repertoire. We combine results from different sister company’s iC-processor (iCubate, Inc.).
types of genomic measurements to increase the power and to identify the contributors to desired
phenotypes, drug response, disease activity, disease severity, or disease stratification. Products Technology
Improving the Lives of Millions of People with Immune-Mediated Inflammatory Diseases iRepertoire’s reagent systems allow iRepertoire’s novel arm-PCR (amplicon
researchers to easily and inexpensively rescued multiplex PCR) is very sensitive,
generate their own high-throughput allowing the amplification of an inclusive
sequencing libraries in the convenience immune repertoire from a small sample.
of their laboratory and analyze their data
with iRepertoire’s proprietary software Services
pipeline at no additional cost. Sequencing of the entire repertoire
for samples is available in addition to
LEADERSHIP iRepertoire’s new service, iPair. In one of
Sara Marsal, MD, PhD the first commercial services of its kind,
paired TCR and BCR chains are sequenced
Founder & Chief Medical Officer from single cells.

Richard M. Myers, PhD CONTACT CONTACT LEADERSHIP
Jian Han, MD, PhD
Founder & Chief Scientific Advisor www.imidomics.com www.irepertoire.com
[email protected] 256.327.0948 Chief Executive Officer
Manuel Lopez-Figueroa, PhD
[email protected]
Chief Operating Advisor
grow with us 19
18 BIOSCIENCE COMPANIES LOCATED AT HUDSONALPHA

iXpressGenes (iXG) is a bioengineering and synthetic biology company focused on Protein Jackson Center is conveniently located in the heart of
Crystallization Services, Instrumentation and Contract Research. Cummings Research Park (CRP), the second largest research
park in the United States. It’s no coincidence that our conference
Products & Services center is located in one of the world’s leading science and
Instrumentation: iXpressGenes has developed a novel technique for identifying early technology business parks.
indications of protein crystallization. This technique is now considered a best practice. Just as CRP is a model for transforming research into business success, Jackson Center is a
The company has developed instrumentation to optimize this important phase of research model for the technical sophistication and specialized services of today’s conference centers.
and drug discovery. Jackson Center works as a “one-stop center” and can handle conference details and all off-site
coordination for your meeting and it even features on-site catering.
Protein Services: iXG provides contract services and products for proteins and enzymes, Jackson Center provides an environment with a level of intimacy that no other meeting facility can
from purification to structural determination. The company has exclusive access to provide. We’re dedicated solely to professional meetings, your conference attendees won’t have
microbes from various extreme environments on earth and on the ocean floor. Some of to mingle with wedding reception guests in the lobby or wade through vacationing guests to get
the extracts are producing antimicrobial activity, which has lead to an innovative research to their meeting. Our size insures that you won’t be overshadowed by “mega conventions” and
contract with the Department of Defense. events. We offer flexible space to accommodate any conference needs and can handle last minute
changes. Parking is a pleasure at Jackson Center, where you can pull up next to the entrance
Research: Scientists at iXG are exploring synthetic biology solutions in the areas of without a problem. No parking decks or long walks.
healthcare, environment and defense. Current research is being conducted on crystals From a technology standpoint, Jackson Center is better equipped than any other facility in the
grown in microgravity on the International Space Station. area, with state-of-the-art audiovisual equipment and an IT support staff that ensures everything
runs smoothly on the day of your event. Jackson Center can handle the most technically
demanding meetings. In addition, our meeting space is specially engineered with appropriate
lighting and acoustics, ergonomic chairs and other features.

Jackson Center — Where business class meets world class.

LEADERSHIP CONTACT CONTACT LEADERSHIP Barry Walker
Joseph Ng, PhD Daniel Laboudiere
www.ixpressgenes.com www.jacksoncenter.net Operations Manager
Chief Executive Officer, Founder 256.426.0413 256.327.9695 Director & Chef
[email protected] Melissa Bennett
20 BIOSCIENCE COMPANIES LOCATED AT HUDSONALPHA [email protected] Jamie Jones
Sales Executive & Accounting
Director of Sales

grow with us 21

With a focus in the fast-growing world of next generation Kymanox is a premier technical products and project
sequencing, Kailos Genetics, through its CLIA Services management company. We are experts in providing our
Laboratory, analyzes DNA for “genetic clues” associated with clients in the Biotechnology, Pharmaceutical, and Medical
drug response, adverse response and diagnosis of disease. Device industries with engineering, scientific, regulatory, and
These clues enable physicians to proactively identify responders and non-responders to process operations support. We help bring products from
certain drug therapies, avoid serious adverse drug reactions that are genetically linked, and bench to patient.
diagnose inherited and non-inherited diseases. Core Competencies

The CLIA Services Laboratory at Kailos Genetics currently provides drug metabolism/ • Quality + Compliance
pharmacogenomic testing services for: • Technical Project Management
• Process Operations
1. Drugs and conditions commonly associated with cardiac disease • Validation
2. Drugs and conditions common associated with mental health issues We differentiate ourselves by offering a broad range of technical services and products with
3. Drugs commonly used to treat pain and pain syndromes turnkey project delivery. We serve clients globally from our headquarters in Durham (RTP),
Kailos Genetics services all physician specialties and has business-to-business relationships North Carolina and branch hubs across the USA.
to leverage its TargetRich™ technology in non-physician and research markets.
LEADERSHIP Nathan Blazei, MEng, CQA
Kailos Solutions Sarah J. (Tillman) Perry
Laboratories can now access reagents and software solutions from Kailos Genetics to Senior Manager, Quality &
develop next generation sequencing assays in their laboratories. The combination of Target President, Owner & Operator Compliance
Rich reagents and Kailos Blue, a cloud-based analysis and reporting software solution,
provides a cost effective and highly scalable platform for next generation sequencing assay Stephen M. Perry Richard Motruk
development.
Chief Executive Officer Director, Manufacturing
LEADERSHIP Randy C. Bachmeyer Operations
Brian Pollock Ash Patel, MBA, CSCP,
Chief Technology Officer CONTACT CONTACT CMQ/QE, CQA
President & Chief Executive
Officer Cheri Walker www.kailosgenetics.com www.kymanox.com Senior Director, Client Services
256.327.9800 1.919.246.4896
Troy Moore Chief Financial Officer Kevin C. Brown, PMP
[email protected]
Chief Scientific Officer General Manager

22 BIOSCIENCE COMPANIES LOCATED AT HUDSONALPHA grow with us 23

Leavendary provides craft brewers customized “big-brewery” biology that fits the craft Microarrays Inc. is a technology company that uses precision
brewing context. Innovative craft brewers continually produce new recipes that create new robotics to manufacture a product called a microarray. Microarrays
and responsive biology requirements for Leavendary. Leavendary ensures brewers have are orderly arrangements of capture probes usually made of DNA
“pitch perfect” yeast, a first-class quality program, and the biology expertise they need to and/or proteins. These probes are able to “capture” biological
succeed in a highly competitive market. information, allowing researchers to rapidly sort through complex
samples and identify the presence or absence of targets of interest. Within healthcare,
Yeast Bio R&D everyone from the patient to the providing institution benefits from the use of array-based
• Delivering pitch-able quantities • Custom yeast strains tools. For the patient, the diagnostic time savings can mean the difference between a
• Banking services • Consulting services positive or negative outcome, especially in regard to infectious diseases.
• Strain selection assistance • Wild yeast “domestication”
Technologies
Microbiology
• Full service testing The technologies developed at MI span the full spectrum of array production, from early project
• Contaminant ID/remediation conception to manufacturing, final quality control and product validation. MI develops all of the
• Drought testing motion-control software, printing robotics and microfluidic deposition technologies used by MI to
provide high throughput capability to any project.
Perfect Pitches, Every Time
Product & Services
Craft Biologists Serving Craft Brewers
DNA/protein/antibody arrays – Array-based tools allow scientists to better understand the
Full Service Beer Biology fundamental aspects of cellular biology, as well as to explore the underlying aspects of human
LEADERSHIP genetic disease. MI provides full custom service for organizations seeking assay development
Peyton McNully assistance.
Founder
Andy Crouse While best known in the industry for microarray production
Chief Scientific Officer and assay development, MI has expanded to include gene
expression laboratory services.

CONTACT CONTACT LEADERSHIP
Joel Peek, PhD
www.leavendary.com www.microarrays.com
256.513.6258 256.327.0544 President & Chief Executive Officer
[email protected]
[email protected]

24 BIOSCIENCE COMPANIES LOCATED AT HUDSONALPHA grow with us 25

Molecular Logic is redefining the way we look at real estate, construction, healthcare, hospi- MVW Nutritionals is a privately held company, with the mission of
tality, food safety, and waste water management. providing leading edge nutritional supplements and vitamins for
There is a rich environment all around us that is teeming with invisible life. “Germs” are ev- persons who have cystic fibrosis and other gastrointestinal disorders.
erywhere and we spend billions of dollars a year on products that treat infections to products Our goal is to deliver exceptional product profiles, coupled with
that alter the beneficial bacteria that are part of our microbiome. This invisible life impacts outstanding service. We believe that quality in what we do, at a
our daily lives. From bacteria and viruses that cause routine or chronic illness to molds and reasonable price, are important, and we are committed to this mission.
mildew that spoil food or destroy artwork or buildings, we have never been able to accurately About the Company
and completely detect and define these microbial populations and specifically and effectively MVW is pleased to offer multivitamin products developed to address the varying needs of
manage them. Molecular Logic has developed a suite of technologies and algorithms that, individuals who have CF. Please see the table below. In 2014, MVW Nutritionals introduced
for the first time, allow unbiased and accurate detection and management of biological pop- the first multivitamin product to address the CF Foundation’s Guidelines for “step increases”
ulations. These tools are routinely applied with high impact in the real estate, hospitality, in vitamin D, and will introduce addition products and services in 2015 to support the man-
sports, healthcare, food safety and wastewater management fields. agement of serum vitamin D levels. The Company is also in the process of expanding it’s
We offer technologies and services to define the biological profile of any sample or location focus in 2015 to support the nutritional aspects of other gastrointestinal disorders.
and determine if the pattern of organisms observed indicates a need for remediation or
presents a threat to safety. Products and Availability
Our products are manufactured at certified cGMP facilities to meet the guidelines set out by
the FDA. Routine testing occurs and every product receives a Certificate of Analysis (“COA”)
upon release by the Quality Assurance team. In addition to making sure that each product
meets its label claim when released, products also undergo stability testing to provide the
confidence that the levels of vitamins and minerals needed in your care are consistent with
the label through product expiration. We believe this is important, as we seek to ensure the
highest standard of quality control from our manufactures for our customers.

LEADERSHIP Outside the US, MVW Nutritionals supports the CF Community in Canada through
Mike Walters Health Canada’s Special Assistance Program; and is working with others on product regis-
tration in several countries.
President
CONTACT CONTACT LEADERSHIP Suzanne Michel
Melanie Vandiver Mike Walters
www.molecularlogic.com www.mvwnutritionals.com Registered Dietician
Operations 256.327.9578 www.cfmultiviatims.com President
[email protected] 855.236.8584
Suzanne Michel Melanie Vandiver
[email protected]
Registered Dietician Operations

26 BIOSCIENCE COMPANIES LOCATED AT HUDSONALPHA grow with us 27

We have an Prozone Water Products Inc., founded by physicist Ron Barnes in 1977, provides
unprecedented unique solutions and leading edge Ozone, Germicidal UV-C, and Advanced Oxidation
opportunity to Process technologies relating to purification processes of fluids, air and surfaces. As
make new genomic a recognized industry leader, Prozone’s Hybrid Cold Plasma and AOP systems deliver
sustainable, on-site production of oxidizers and DNA modification without harmful
discoveries. by-products. Designing safe and efficient methods for industrial and commercial
- Richard Myers, PhD water treatment, Prozone has manufactured and supplied over a million purification
systems throughout the world for point-of- use drinking water, cistern and well water systems, aquatics systems, plant, fruit,
President and Science Director for HudsonAlpha and vegetable processing systems, fisheries, hatcheries, cooling towers, recreational water, waste and sewage water treatment.
Through its research, Prozone continues to innovate oxidation systems technology development for International organizations
such as United Nations, NASA, Universities, Corporations and the Departments of Agriculture, Defense and the Interior.

Ploid is a next generation, whole human Testing Key Technologies
genomics stroage and pipeline company. Prozone’s studies and testing focuses on Ozone and Advanced Oxidation Prozone Water Products specializes in small to medium
Through state-of-the-art, encrypted servers, Processes as a means of purifying water; as a biocide for Biofilms; sized ozone and hydroxyl producing systems and has ~ 35
Ploid provides a safe, simple, and easy solution and the destruction of harmful microbes like viruses, bacteria, molds US and international patents in the following key areas:
to storing your genomic data. and toxic chemicals. Elimination of Legionella, Cryptosporidium,
E-coli, Pseudomonas, Staphylococcus, MRSA, C-Diff and other patho- • Ozone Generation using Hybrid Cold Plasma Germicidal VUV
gens found in hospitals, cruise ships, recreational facilities, and reha- – Designed to harness the VUV spectrum of 185nm photo-
bilitation facilities is a high priority. Prozone’s continuous study of the chemical production of ozone and 254nm germicidal DNA
efficacy of Ozone and AOP technologies on the destruction of biofilms modification
in water supply lines in cooling towers, closed loop bodies of water and
throughout buildings are critical to the protection of human health. • Ozone and UV-C Advanced Oxidation Processing (AOP) –
These studies are being examined to produce sustainable, on-site prod- Photochemical method in which photons in the UV spectrum
ucts that will ensure the safe and cost effective processing of vegeta- convert ozone in the presence of water to Hydroxyl Radicals
bles, fruit, meat and preparation of food, storage, and preservation.
• Oxygen Fed Corona Discharge Air Cooled Ceramic Flat Plate
Ozone Generators

• Contacting Systems using Bypass Dynamic Venturi Injectors
and Serpentine Counter-Flow Structures

LEADERSHIP CONTACT CONTACT LEADERSHIP
Peyton McNully Ron Barnes
www.ploid.io www.prozoneint.com
Founder, Chief Executive Officer 256.539.4570 Founder & Chief Executive Officer

Brandon Kruse [email protected] Cherie Brook

Founder President

28 BIOSCIENCE COMPANIES LOCATED AT HUDSONALPHA grow with us 29

Serina Therapeutics, Inc. is a privately-held pharmaceutical The Smith Family Clinic for Genomic Medicine, powered by HudsonAlpha,
company that is advancing novel therapeutics for Parkinson’s Children’s of Alabama, and UAB Medicine, uses whole genome sequencing to
disease, restless leg syndrome, cancer, epilepsy, inflammation diagnose rare, undiagnosed and misdiagnosed disease. A clinical geneticist
and pain using its proprietary, patented polymer technology. uses data from the genomic sequence to clinically interpret genetic variants
The company has created new pharmaceutical candidates using to identify the cause of disease.
polyoxazoline (POZ) – a safe, water-soluble polymer to which
a variety of small molecules, proteins, peptides and DNA can be attached. This attachment confers a unique pharmacokinetic profile that Mission and Vision
is markedly different from the parent compound. This profile may confer advantages in terms of safety and efficacy. In general, molecules Through the power of genomics, the Smith Family Clinic for Genomic Medicine solves diagnostic
attached to POZ stay in the body for a much longer period of time – and can be precisely tuned to achieve the desired therapeutic profile. mysteries and provides long-sought diagnoses to parents and physicians. The clinic’s mission
In addition to progressing its CNS-focused pipeline, Serina Therapeutics has partnered its technology with two of the top ten is not only to help find answers, but also to give patients the best clinical care and a positive
pharmaceutical companies worldwide, and is actively seeking new partnerships. medical experience.
Who Are Our Patients?
Trials & Testing Key Technology The Smith Family Clinic for Genomic Medicine sees patients who...

Serina Therapeutics has advanced its first proprietary compound, SER-214, into Novel polymer drug delivery platform based on • Have a disease with no definitive diagnosis
clinical trials in patients with Parkinson’s disease (PD). SER-214 is a once-per-week polyoxazoline - POZ. Serina Therapeutics also • Have a diagnosis that doesn’t “quite fit”
injectable that provides continuous drug delivery of a potent dopamine agonist known holds the global exclusive license to metal-cat- • Have had extensive tests already
as rotigotine. Continuous dopaminergic stimulation has been a long-sought clini- alyzed “click chemistry” for the development of • Want to end the search for answers
cal strategy in patients with PD for decades, and SER-214 is unique in this mode of POZ-therapeutics. Types of Diseases We Diagnose
action. SER-214 should obviate the phasic peak and trough of many oral drugs used Genetic diseases can be inherited, even though no one else in the family have the same
to treat PD – thus preventing “wearing off” and onset of dyskinesia. The Phase 1a symptoms or even “just happen” in nature. At the Smith Family Clinic, we offer the best test
trial successfully completed in May 2017. Data show that SER-214 is safe and has first, whole genome sequencing, which paints a full picture of your DNA and offers the best
predictable pharmacokinetic properties. Serina is planning to initiate Phase 2 trials chance at ending your journey for a diagnosis.
of SER-214 in patients with Parkinson’s disease and moderate to severe Restless Leg
Syndrome. For more information on the Phase 1a trial, please visit https://clinicaltri-
als.gov/show/NCT02579473.

LEADERSHIP Tacey X. Viegas, PhD CONTACT CONTACT LEADERSHIP Meagan Cochran, MS, CGC
Randall W. Moreadith, David Bick, MD
MD, PhD Chief Operating Officer www.serinatherapeutics.com www.smithfamilyclinic.org Genetic Counselor
256.327.0566 256.327.9640 Medical Director
President & Chief Executive Mike D. Bentley, PhD [email protected] Whitley Kelley, MS, CGC
Officer [email protected] Carol Aiken, CMM, CPAR
Chief Scientific Officer Genetic Counselor
Brendan P. Rae, PhD, JD Clinic Administrator
J. Milton Harris, PhD
Chief Business Officer Kelly East, MS, CGC
Chairman
Genetic Counselor Lead

30 BIOSCIENCE COMPANIES LOCATED AT HUDSONALPHA grow with us 31

Sulfilatec, Inc. is a biotech company that is Relocating to SynVivo is a physiological, cell-based microchip platform that provides a morphologically
dedicated to helping patients with heart and HudsonAlpha was and biologically realistic microenvironment allowing real-time study of cellular behavior,
kidney diseases. Heart disease is the leading drug delivery and drug discovery.
cause of death, including among patients with one of the best Synvivo, LLC was founded in 2014 as a spin-out from CFD Research Corporation (CFDRC) to
kidney disease. Sulfilatec is discovering and decisions we have commercialize with the Synvivo family of cell-based assays. Synvivo, whose name is derived
developing new therapeutics for these patients. made as a company. from synthetic in vivo, is a disruptive technology with a goal to revolutionize drug discovery and
As a company, we are committed towards precision medicine by providing the most realistic and dynamic in vitro platform for cellular
leveraging great science to the benefit of HudsonAlpha behavior and drug response. The two high-tech domains of microfluidics and bioengineering have
patients. Our drug development platform provides a enabled Synvivo scientists to analyze and visualize how drugs behave in real-time offering a true
harnesses groundbreaking discoveries remarkable breakthrough in drug development. Even more importantly, Synvivo is at the forefront of truly
regarding the novel biologic activities of bromide personalized, precision medicine with its technology’s ability to show, in real-time, how a patient
that have been published in top-tier scientific environment for will respond to different drugs or combination therapies.
journals. Our lead drug candidates are designed building and growing
to act on key molecular pathways in heart biotech companies. CONTACT LEADERSHIP
failure, chronic kidney disease, and certain - Chris Cummings, PhD Kapil Pant
ESRD-associated comorbidities. Every day, we www.synvivobio.com
diligently work to translate these discoveries President and Chief Executive Officer, Sulfilatec 256.384.4726 President & Chief Executive Officer
into new treatments for patients and are
always open to exploring new collaboration and CONTACT [email protected] B. Prabhakar Pandian
partnership opportunities.
615.618.4833 Chief Technology Officer
Inspired by biology. Motivated by patients. Sulfilatec. [email protected]
Gwen Fewell
LEADERSHIP
Chris Cummings, PhD Chief Commercial Officer

President & Chief Executive Officer grow with us 33

32 BIOSCIENCE COMPANIES LOCATED AT HUDSONALPHA

At transOMIC Technologies, we believe deeply in the power of
science and technology to advance the understanding of biological
systems to ultimately improve the quality of life.

Thermo Fisher Scientific Inc. is the world leader in serving science, with Our company provides innovative tools and strategies for life
50,000 employees in 50 countries. Our mission is to enable our customers to science researchers to help them unravel genetic complexity and to understand disease
make the world healthier, cleaner and safer. We help our customers accelerate development. This mission, coupled with a good understanding of the tools that life science
life sciences research, solve complex analytical challenges, improve patient researchers need, drives our focus to be a research partner, delivering technologies in a
diagnostics and increase laboratory productivity. Our four premier brands – Life cost-effective and technically supported manner to enable discovery across the genome.
Technologies, Thermo Scientific, Fisher Scientific and Unity Lab Services – offer
an unmatched combination of innovative technologies, purchasing convenience Our Portfolio transEDIT CRISPR-Cas9 Genes for All Species
and comprehensive support. Reagents for Genome-editing Through an arrangement
Thermo Fisher Scientific, Inc. serves customers through two premier brands, shERWOOD UltramiR Next with the National Institutes of
Thermo Scientific and Fisher Scientific. Thermo Scientific offers customers Generation shRNA Tools for Transomic Technologies has Health, Transomic Technologies
a complete range of high-end analytical instruments, as well as laboratory partnered with Dr. Greg Hannon houses one of the largest
equipment, software, services, consumables and reagents to enable integrated RNA Interference (RNAi) and Dr. Simon Knott of Cold repositories of gene content
laboratory workflow solutions. Fisher Scientific provides a complete portfolio RNA interference (RNAi) is Spring Harbor Laboratories made available to researchers
of laboratory equipment, chemicals, supplies and services used in healthcare, a technology used to control to provide a powerful and across the globe. This vast
scientific research, safety and education. the expression of genes by extremely versatile set of tools collection of genes coupled
‘knocking down’ the production for genome-editing. These tools with our gene-editing tools and
of protein that a gene codes harness the newly discovered RNA interference tools gives
for. Like genome-editing CRISPR-Cas9 technology. researchers a one-stop-shop
tools, RNAi tools are used to Genome-editing allows for planning their gene-centric
create cellular models for researchers to ‘edit’ genes in research experiments.
understanding our genes and a research setting by changing
the role they play in disease. the sequence of DNA for any
Transomic Technologies is given gene. Editing these DNA
the exclusive provider of sequences gives researchers
the next generation of RNAi the cellular models needed for
tools created in collaboration understanding disease, which
with Cold Spring Harbor eventually leads to new drugs
Laboratories. or therapies.

LEADERSHIP CONTACT CONTACT LEADERSHIP Rusla du Breuil
Ian Cavanaugh Blake Simmons
www.thermofisher.com www.transomic.com Chief Technology Officer
Research Antibody Data Admin [email protected] 256.327.9510 Chief Executive Officer

34 BIOSCIENCE COMPANIES LOCATED AT HUDSONALPHA [email protected]

grow with us 35

Testing & Laboratory Work High throughput Ubiquity Genomics provides tools for targeted
sequencing is providing DNA sequencing. The company’s proprietary
Trideum Biosciences is an award-winning pre-clinical CRO technology allows researchers to focus genetic
that engages Ph.D. scientists and skilled technical staff to a foundation for both and epigenetic analyses on large regions of
design, troubleshoot, conduct, analyze and report the scientific individualized patient the genome at a fraction of the cost of other
data. Our customized approach for each client and the insights therapies [and] CATCH- commercially available approaches. Ubiquity
we provide lead to improved and faster therapeutic, diagnostic Seq utilizes a simple Genomics offers customized sequencing
and medical device product development. approach for the targeted services, as well as pre-made targeting kits.
capture of any genomic The first pre-made kit is Complete MHC, which
• Microbiology Testing and Analysis region for which mapped enables scientists to sequence the entire
• Antimicrobial Efficacy Testing MHC locus, a region of great importance to
• Biofilm Testing clones exist, and is immunological disease research. Ubiquity also
• Bacteriophage Testing designed specifically offers kits for the enrichment of human DNA
• Extraction of high-quality genomic material for next-generation from contaminated sources, such as saliva.
• Customized testing protocols These kits will also deplete human DNA when
sequencing. the research is focused on the microbiome.
Consultation for Scientific Endeavors
- Devin Absher, PhD
We have a proven track record of scientific consultation for various clients.
• Providing a path-forward for product development Chief Executive Officer, Ubiquity Genomics
• Research Study Design
• Data Review and Reporting
• Scientific Assessment of various products and technologies

• Preparation and Review of scientific documents including grants

Research & Analysis
We conduct precise and thorough GLP-compliant laboratory testing to produce reliable, high
quality data. Our expertise in infectious diseases and wound care enable us to effectively
assist University and government research as well as domestic and international companies
seeking to bring products to the U.S. market.

LEADERSHIP Mina Izadjoo, PhD CONTACT CONTACT LEADERSHIP
Van Sullivan Devin Absher, PhD
Chief Science Officer www.trideumbiosciences.com www.ubiquitygenomics.com
President 256.704.6100 256.327.9833 Chief Executive Officer
[email protected]
[email protected]

36 BIOSCIENCE COMPANIES LOCATED AT HUDSONALPHA grow with us 37

Volatile Analysis Corporation (VAC) is a privately held company that Talented Workforce
specializes in volatile chemical utilization, detection, measurement,
and olfaction. Small, volatile (propensity to exist as gas) chemicals are
responsible for all aromas/odors, and quite important in biological and
industrial applications.

Technology Research & Development Southern Living HudsonAlpha is surrounded by a community of talented, skilled and intelligent individuals mo-
Huntsville has one of the most tivated to apply knowledge in ways that create tangible benefits. Engineering in North Alabama
VAC is an analytical problem-solving and VAC is a research and development company favorable salary-to-cost-of-liv- propelled rockets into orbit, landed men on the moon and sent information-seeking probes
consulting company specializing in the that focuses on volatile chemical applications. into deep space. For more than 50 years, Huntsville has applied its expertise to aviation and
detection, identification, and measurement Opportunities are numerous and include: 5ing ratios in the Southeast. missiles at the U.S. Army’s Redstone Arsenal, and has accomplished great feats for NASA and
of trace level and ultra-trace level chemicals the Army. HudsonAlpha is applying the same passion and drive to the promise of genomics and
responsible for odor and aroma. An expert staff • metabolomics (disease diagnosis via trace Top use of biotechnology to improve the way we approach health and disease.
utilizes combinations of analytical chemistry level volatile chemical biomarkers present in
and sensory analysis to develop strategies for the breath, perspiration, urine of humans and Alabama is a nationally recog- The Huntsville metro area has the highest per capita concentration of engineers and
completely solving or mitigating costly odor animals) nized workforce recruitment and technology workers in the country, and more than half of Huntsville area residents
problems perceived by consumers as indicative training program as one of the Top have degrees in engineering and science-related fields.
of tainted, potentially dangerous, or just • genetic modification impact on the volatile Five workforce training agencies
unacceptably poor quality products. chemical profiles of plants and animals in the United States, according to The colleges and universities in Huntsville and the surrounding areas offer two-year,
four-year and advanced degrees in the biosciences and related fields. Alabama is a
VAC works with industries where aroma/odor • chemical communication (identification 8thArea Development, Summer 2015. “right to work” state. The state promotes economic growth by offering customized
is important. Examples include paper and and measurement of chemicals utilized for training and support services for new and expanding businesses.
packaging, pharmaceutical, food and beverage, biological system communication for example Alabama ranks No.8 in the
cosmetic, apparel, manufacturing (light and pheromones) United States for biopharma- Biosciences are a priority for the city
heavy), and automotive. The analytical/sensory ceutical job creation, according of Huntsville, Madison County, the
division provides deployable aroma/odor • olfaction and aroma activity to Site Selection Magazine and state of Alabama and many of our re-
analysis and panel training. Sensory trained Hardware and methods for concentrating and Clustermapping US. gional economic development part-
staff review industrial processes and coordinate identifying volatile chemicals and their olfaction ners. HudsonAlpha is working with
odor remediation efforts. Analytical services properties are also active research areas. the economic development partners
specializes in quantification of trace level and Patent-pending technology includes devices that to strengthen policies and incentives
ultra-trace level (ng/g or parts per trillion and enhance chemical detection for the life sciences industry.
lower) chemicals responsible for odor and
aroma. grow with us 39

LEADERSHIP Russell Bazemore, PhD CONTACT
Katherine Bazemore
Senior Vice President of Research www.volatileanalysis.com
President & Chief Executive & Development 256.486.3531
Officer [email protected]
Chris Christianson, PhD
Matthew Shirley
Senior Vice President, Analytical
Chief Operating Officer Services

38 BIOSCIENCE COMPANIES LOCATED AT HUDSONALPHA

Why Locate on HudsonAlpha’s Culture of Collaboration
Collaborative Campus?
Acquisition, analysis, and application of genomic research happening here inspires innovations in life sciences
The primary benefit of establishing a startup, fostering an early stage company, or companies. HudsonAlpha offers turnkey or build-to-suit office/lab space on a state-of-the-art biotech campus
relocating a mature enterprise to HudsonAlpha is collaboration with leading-edge with an energizing environment, blending research, education, medicine, and commercialization.
intellectual talent that provides opportunities for life sciences companies of all
stages to grow and expand. 2HudsonAlpha Campus is part of - Entrepreneur magazine, August 2013 “ Huntsville is NerdWallet’s second best place for tech
jobs in the U.S.”
Advantages of Cummings Research Park the nd “Huntsville is the #3 city where your
money goes the farthest.” - Forbes, April 2015
The 152-acre HudsonAlpha Institute for Biotechnology campus is located in Cummings Research Park, 4largest research park in the
the second largest research park in the United States. Cummings Research Park co-locates Fortune - Boston Business Journal, October 2015 In Huntsville, you can do your research, development,
500 companies with local and international businesses specializing in a range of high-tech industries: United States and engineering, and manufacturing all in the same location. This
aerospace and defense, hardware and software development, engineering, and research and devel- Growth Impact Study
opment. The HudsonAlpha campus is minutes from the Port of Huntsville (Huntsville International th systems approach is why Huntsville continues to be on the
Airport and International Intermodal Center) and convenient to Interstate 565, Interstate 65, and the radar for companies looking to innovate and create.
Tennessee River Waterway system. largest research and technology
park in the world. - Tommy Battle
Grow with Us
HudsonAlpha coordinates Mayor, City of Huntsville
Locating on HudsonAlpha’s campus offers any
size company access to the cutting edge of bio- closely with Associate Unrivaled Inspiration & Business Advantages
technology and flexibility to grow.
Superior shared amenities and administrative Companies to foster growth • Campus address with shared spaces and centralized services includ-
support, unavailable in conventional office ing: atrium/cafe, security, meeting spaces, waste management and
settings, power your progress and provide and ensure success. recycling, and shipping and receiving.
space for expansion.
- Carter Wells • Labs built to NIH standards for biosafety, with single pass air and
40 BIOSCIENCE COMPANIES LOCATED AT HUDSONALPHA emergency power, LEED certified space, and electric vehicle (EV)
Vice President for Economic charging station on campus.
Development, HudsonAlpha
• Administrative services and strategic support: investor forums, job
postings, marketing resources, networking, world-class human and
plant sequencing and analysis services.

• Fully-managed, on-site IT services with multiple, diverse path ISP up
to 200G, customized net topologies, VPNs, phone, and voicemail that
provides reliability, control, capacity, and speed.

grow with us 41

Next door to discovery - with space, To learn more about the advantages of
talent, and bandwidth to grow. HudsonAlpha and locating your bioscience

company in Huntsville, Alabama, visit
hudsonalpha.org/innovate.

Carter Wells, Vice President for Economic Development 601 Genome Way, Huntsville AL 35806
[email protected] | 256.327.5241 T: 256.327.9591

www.hudsonalpha.org

Amy Sturdivant, Economic Development Specialist
[email protected] | 256.327.9591